Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals

Coherus Oncology, Inc.

Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.
Approval clears key milestone for divestiture of UDENYCA (pegfilgrastim-cbqv) franchise under Dec 2, 2024 Asset Purchase Agreement.
Special Meeting held virtually on March 11, 2025; 115,890,186 shares outstanding as of Jan 27, 2025 record date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.